News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

 

Thalidomide prolongs disease stabilization in those with recurrent glioblastoma.


Posted on: 02/07/2004

Angiogenesis Weekly, Feb 13, 2004 p3

Thalidomide prolongs disease stabilization in those with recurrent glioblastoma.

Full Text: COPYRIGHT 2004 NewsRX

2004 FEB 13 - (NewsRx.com & NewsRx.net) -- Thalidomide prolongs disease stabilization in those with recurrent glioblastoma.

"Thalidomide shows antiangiogenic activity and it has been successfully employed in various tumors. Considering the poor therapeutic options for glioblastoma and the role of angiogenesis in malignant glioma cells growth, we investigated the therapeutic activity of thalidomide in patients affected by recurrent glioblastoma. Inclusion criteria were: recurrent glioblastoma pretreated with surgery and radiotherapy, age greater than or equal to18 years, adequate performance status, hematological, renal, and hepatic functions," scientists in Italy report.

"Exclusion criteria included severe underlying diseases, neuropathy or concurrent radiotherapy. Eighteen patients entered the study, 17 of whom were assessable for toxicity and response. Most of patients were pretreated with chemotherapy (77.8%)," said A. Morabito and colleagues, San Filippo Neri Hospital, Division of Medical Oncology.

"Thalidomide was well tolerated: the most common side effects were constipation (76.5% of patients), somnolence (47%), and peripheral neuropathy (11.8%). One minimal response (MR) and 8 stable disease (SD) were observed, with an overall clinical benefit of 52.9%. Median time to progression and median overall survival (OS) for responders was 25 weeks (range 12-40) and 36 weeks (range 16-64), respectively."

"In conclusion, thalidomide induces modest side effects and it may be considered a valid therapeutic option for patients with recurrent glioblastoma," researchers decided.

Morabito and colleagues published their study in Oncology Reports (Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncol Rep, 2004;11 (1):93-95).

For more information, contact G. Gasparini, San Filippo Neri Hospital, Division Med Oncology, Via Martinotti 20, I-00135 Rome,


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740